Ritonavir - Drug-Drug Interactions Leading to Potentially Serious and/or Life Threatenng Reactions
- Co-administration of ritonavir with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of ritonavir on the hepatic metabolism of certain drugs.
- Review medications taken by patients prior to prescribing ritonavir or when prescribing other medications to patients already taking ritonavir
TECHNIVIE; VIEKIRA PAK; VIEKIRA XR - Risk of Hepatitis B Virus Reactivation in Patients CoInfected with HCV & HBV
- Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with TECHNIVIE. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated
MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA
- Contraindicated drugs include antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine), Antimigraine (dihydroergotamiine, ergotamine), sedative/hypnotics (midazolam, triazolam), GI motility agent (cisapride), and neuroleptics (pimozide)
- For list of drugs to be used with caution, see package insert.
- Ritonavir is an inhibitor of CYP450 CYP3A
Patient Counseling Information